---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-25-001555"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:31:48.741630+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Arcturus Therapeutics Reports Q3 2025 Net Loss of $13.5M, Progresses ARCT-032 and ARCT-810 Programs

## Summary
- Q3 2025 revenue was $17.2M, down $24.5M from prior year; net loss $13.5M ($0.49 per share) vs $6.9M loss in Q3 2024.
- ARCT-032 Phase 2 interim data: inhaled 10mg daily over 28 days well tolerated; mucus burden reduced in 4 of 6 Class I CF adults per HRCT scans.
- Company plans a 12-week safety and efficacy study of ARCT-032 in up to 20 CF participants starting H1 2026.
- FDA changes delayed U.S. BLA filing for KOSTAIVE indefinitely; additional cost reductions planned in Q4 2025 to extend cash runway into 2028.
- ARCT-2304 pandemic flu vaccine candidate induced humoral immune response after single dose at all tested levels, supporting further development.

## SEC filing metadata
- accession: 0001193805-25-001555
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380525001555/0001193805-25-001555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380525001555/e664953_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-25-001555
- JSON: https://secwatch.observer/filing/0001193805-25-001555.json
- Plain text: https://secwatch.observer/filing/0001193805-25-001555.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.